| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3992840 | Journal of Thoracic Oncology | 2007 | 7 Pages |
Abstract
Weekly irinotecan and cisplatin combined with radical TRT (63 Gy) is active and fairly well tolerated in locally advanced NSCLC. In combination with fixed-dose cisplatin (25 mg/m2 per week), the maximum-tolerated dose of irinotecan is 30 mg/m2 per week.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Corey J. MD, Robert MD, Samuel PhD, Steven MD, Benjamin MD, Christine RN, Eric MD, Michael MD, Nicos MD, Chao MD, Joseph MD,